ACQUISITIONS and MERGERS

Meghan Scanlon, senior vice president and president, Urology, Boston Scientific. “By closing this acquisition, we’re pleased to welcome the Axonics team into Boston Scientific. The addition of the Axonics product portfolio enables us to expand into sacral neuromodulation, a high-growth adjacency for our Urology business, while bringing a comprehensive portfolio of products to patients around the world who are seeking tailored treatment options based on their life stage and incontinence severity.”

Nick Spadea-Anello, global president, Electrophysiology, Boston Scientific said, "We believe the addition of the Cortex technology complements our electrophysiology portfolio with a differentiated cardiac mapping offering to assist with complex AF cases."

“We have maintained an advisory relationship with Kewaunee for many years and are proud to have played a role in the successful strategic acquisition of Nu Aire by Kewaunee,” added Evan Tomaskovic, Managing Partner at Carl Marks Advisors. “It is gratifying to assist a 100-year-old business complete a key acquisition of a more than 50-year-old family-owned business, fortifying the legacies of both world-class organizations.”

With the acquisition complete, ZOLL will immediately make available to customers the bellavista®, fabian®*, LTV®, and 3100 HFOV product lines alongside ZOLL’s other respiratory care offerings. For these acquired product lines, all ventilators and associated consumables, service parts, accessories, and service program offerings will continue to be sold where currently available. Existing Vyaire contact channels will remain available for use during a transition period. Customers can also contact ZOLL at ventsales@zoll.com.

Getinge paid approximately USD 253 million in cash upon completion of the acquisition, on a cash and debt free basis. The earn-out payments are expected to be paid between 2024 and 2026 if agreed upon regulatory and financial performance milestones are achieved and may exceed USD 224 million in aggregate. The initial payout related to the acquisition has been financed through a bridge loan provided by SEB. The acquisition is expected to have a slightly negative impact on Getinge's adjusted earnings per share in 2024. Getinge anticipates a positive contribution on adjusted earnings per share starting in 2028.

"The health care industry is being redefined by AI, robotics, and autonomous solutions, and our team continues to accelerate the application of these new technologies to improve the quality and cost of patient care around the world," said Tom Polen, chairman, chief executive officer and president of BD. "Today, BD is proud to welcome BD Advanced Patient Monitoring, whose leading technologies, AI-enabled solutions and strong innovation pipeline expand our portfolio of smart, connected care solutions, create significant value for customers, and put BD at the forefront of enabling the future of health care."

“After a comprehensive evaluation, we are confident PaceMate is the best organization to service Paceart customers and their future cardiac data workflow needs,” said Kweli P. Thompson, M.D., M.P.H., senior vice president and president, Medtronic Cardiac Rhythm Management. “PaceMate offers best-in-class cardiac data management solutions and will provide excellent ongoing support to Paceart customers.”

The acquisition of Hobson further strengthens Vantedge's position as a nationwide manufacturing partner to blue-chip medical OEMs and broadens Vantedge's consumable portfolio offering. Since Aterian's acquisition of Vantedge in May 2018, Vantedge has acquired five medical technology businesses, established and fully commercialized new production facilities, completed substantial capital equipment capacity expansion and significantly invested in human capital throughout the organization. Vantedge now operates nine facilities across the United States with more than 1,200 employees.

“Respiratory care has been central to ZOLL’s business strategy for many years,” said Jon Rennert, CEO of ZOLL. “If the acquisition is successfully completed, adding Vyaire’s ventilators to ZOLL’s product portfolio will enhance our ability to serve a broader range of clinicians and patients.”